{
    "clinical_study": {
        "@rank": "101037", 
        "brief_summary": {
            "textblock": "To characterize the pharmacokinetics of orally administered FLT (in a liquid formulation)\n      after single doses in both the fed and fasting states; to assess the effect of food on the\n      oral bioavailability of FLT"
        }, 
        "brief_title": "An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Positive ELISA test confirmed by Western blot analysis.\n\n          -  Asymptomatic.\n\n          -  Willing to sign an informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Oral candida infection documented by morphology or by a response to antifungal\n             therapy within two months prior to study entry.\n\n          -  Oral hairy leukoplakia at any time prior to entry.\n\n          -  Temperature > 37.8 C.\n\n          -  Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in\n             situ.\n\n          -  Significant chronic underlying medical illness which would prevent continuous\n             participation in this clinical trial.\n\n          -  Unwilling to sign an informed consent.\n\n          -  Zidovudine induced hematological toxicity.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Therapy with antiretroviral drugs or immunomodulators within seven days before entry.\n\n          -  Therapy with any investigational drug during the preceding 30 days.\n\n        Patients may not have:\n\n          -  Oral candida infection documented by morphology or by a response to antifungal\n             therapy within two months prior to study entry.\n\n          -  Oral hairy leukoplakia at any time prior to entry.\n\n          -  Temperature > 37.8 C.\n\n          -  Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in\n             situ.\n\n          -  Significant chronic underlying medical illness which would prevent continuous\n             participation in this clinical trial.\n\n          -  Unwilling to sign an informed consent.\n\n          -  Zidovudine induced hematological toxicity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002260", 
            "org_study_id": "054C", 
            "secondary_id": "81-3"
        }, 
        "intervention": {
            "intervention_name": "Alovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alovudine", 
                "Dideoxynucleosides"
            ]
        }, 
        "keyword": [
            "Biological Availability", 
            "alovudine", 
            "Food"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002260"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lederle Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1992"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612"
    }
}